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1. Introduction
Type 1 diabetes (T1D) is an insulin-dependent diabetes because of insufficient insulin pro‐
duction by the pancreatic islet β cells. Although the pathogenic mechanism of T1D is not yet
completely clear, the current view of T1D pathogenesis is that under certain genetic back‐
ground, exogenous and/or endogenous factors trigger autoimmunity against islet β cells in
the pancreas causing β cell damage and subsequent insufficiency of insulin production [1,
2]. About two decades ago, it was first demonstrated that T cells specific to β cell antigens
were activated and participated in the pathogenesis of T1D [3, 4]. A great deal of work fol‐
lowing these reports in both animal models and humans has provided convincing data fur‐
ther supporting T1D is a T cell-mediated autoimmune disease. On the other hand, the
evidence showing that majority of T1D patients have high titers of autoantibodies against
islet β cells [5, 6] suggests that self-reactive B cells must also be involved in the autoimmune
process. The role of B cells in the pathogenesis of T1D was further supported by the recent
research and clinical data demonstrating B cell depletion by anti-CD20 antibodies delayed
the disease process.
The clinical presentation of T1D is preceded by a period of time of active autoimmune re‐
sponse occurring in the pancreatic islets. When overt diabetes occurs, approximately 95% of
islets are destroyed. Therefore, tremendous efforts have been pulled in halting or slowing
down autoimmune process for the purpose of preventing T1D. Several clinical trials in T1D
prevention have been put forward. However, there is, thus far, no effective approach to the
prevention of human T1D despite that many have shown promising results in T1D animal
models. Further effort is needed to discover new ways to prevent T1D. Importantly, from a
practical point of view, reversing overt diabetes is much needed. In this chapter, we will fo‐
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cus on recent research in immune intervention of disease process in T1D including modula‐
tion of T cells, B cells by antibodies as well as cellular therapies such as autologous
hematopoietic stem cell transplantation (ASCT), treatment with mesenchymal stem cells
(MSC) and cord blood transplantation.
2. Antibody-based therapies of type 1 diabetes
In this section, we will discuss antibody-based therapy in T1D including therapies using an‐
ti-CD20 and anti-CD3 antibodies as well as anti-thymocyte globulin.
2.1. Anti-CD20 antibody therapy in type 1 diabetes
B cells are immune cells that produce antibodies when stimulated by exogenous or endoge‐
nous antigens. Several autoimmune diseases are associated with self-reactive B cells such as
systemic lupus erythematosus and idiopathic thrombocytopenia. Reports have shown that
depletion of B cells ameliorates such autoimmune conditions [7-9]. CD20 is highly expressed
on the surface of mature B cells and is the B cell-specific marker. Thus, anti-CD20 antibody
has been employed for the in vivo depletion of B cells. The FDA-approved drug, anti-human
CD20, Rituximab has been used clinically for CD20+ B cell lymphoma for over a decade and
largely improved the survival of patients with B cell lymphoma. Recently, anti-CD20 thera‐
py was tested in several clinical trials for the treatment of B cell-mediated autoimmune dis‐
eases and demonstrated promising efficacy including a clinical study for the new onset T1D
patients [10]. We will get into details on how anti-CD20 therapy works, its efficacy in treat‐
ing T1D, the potential adverse effects as well as the issues to be solved in the future.
2.1.1. The mechanisms of action of anti-CD20 therapy
It is generally believed that the effect of anti-CD20 therapy results from the depletion of B
cells by the anti-CD20 antibodies in vivo. However, the mechanism of action of anti-CD20
therapy is largely beyond B cell depletion. Several mechanisms have been proposed con‐
cerning the action of anti-CD20 therapy.
2.1.1.1. Complement activation in anti-CD20 therapy
Complement activation by binding the Fc fragment of the antibody leads to cell lysis, or
named complement-dependent cytoxicity (CDC). Complement-dependent cell lysis is con‐
trolled by the degree of complement activation and regulated by a series of complement in‐
hibitory proteins, such as CD35, the complement receptor type 1; CD46, the membrane
cofactor protein; CD55, the decay accelerating factor; and CD59, the membrane inhibitor of
reactive lysis. It appears that the ability of CD20 to move into lipid rafts is needed for CDC
to occur [11]. Some protein kinase pathways are also involved in regulating CDC activity,
e.g. the activation of PKC, PKA and MEK is associated with B cell resistance to CDC [12].
Furthermore, complement activation has other effects besides cell lysis, such as depositing
C3, C3b and additional CD3b breakdown products on the cell surface [13].
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2.1.1.2. Antibody-dependent cellular cytoxicity (ADCC)
ADCC effect in anti-CD20 therapy represents killing of target cells (B cells) by the effector
cells that are activated by binding the Fc fragment of anti-CD20 antibody bound on B cells.
Members of the Fcγ receptor family are expressed on monocytes, macrophages and granulo‐
cytes, and include the activating high-affinity FcγRI (CD64) and low-affinity FcγRIIIA
(CD16), as well as the inhibitory low affinity FcγRIIB (CD32). FcγRIIB is believed to be a key
regulator on B lymphocytes [13-15]. ADCC was recently demonstrated as an important in
vivo mechanism of anti-CD20 action [13].
2.1.1.3. CD20 binding induces B cell apoptosis
Although the major role of anti-CD20 therapy is cell and complement-mediated cell lysis,
there is evidence that anti-CD20 antibody mediates B cell death through inducing B cells to
undergo apoptosis [16]. Anti-CD20 antibody, such as Rituximab induces B cell apoptosis
through activation of caspase-3 [17], whereas the FAS ligand/FAS death pathway does not
seem necessary. Therefore, the mitochondrial-dependent pathway is likely the death path‐
way induced by anti-CD20. The role of bcl-2-dependent pathways remains unclear.
Most research on the mechanisms of action of anti-CD20 therapy was conducted in B cell
lymphoma to study how anti-CD20 therapy kills lymphoma tumor cells but not normal B
cells. Anti-CD20 antibody therapy may work differently when used to modulate normal ma‐
ture B cells. Although the existing evidence shows that anti-CD20 therapy induces regulato‐
ry T cells or regulatory B cells in autoimmune settings [18-20], the mechanisms of action of
anti-CD20 in modulating normal mature B cells are not fully understood and need to be fur‐
ther addressed. The insight into the mechanisms of action of anti-CD20 therapy in autoim‐
mune settings is of great importance in guiding anti-CD20 therapy in autoimmune diseases.
2.1.2. Animal studies on anti-CD20 therapy in T1D
NOD (nonobese diabetes) mouse is an animal model of human T1D. In this strain of mice,
diabetes starts to occur usually around 10 weeks of age. Tremendous measures have been
tested for T1D prevention in NOD mice including anti-CD20 therapy. Hu reported for the
first time that anti-CD20 therapy not only prevented but also reversed T1D in humanized
NOD mice (Hu-NOD, CD20 transgenic mice). Furthermore, anti-CD20 therapy-modulated B
cells can transfer diabetes-protective effect when co-transferred with diabetogenic spleen
cells in NOD-scid mice, suggesting post anti-CD20 depletion the reconstituted B cells might
acquire tolerogenic, or regulatory capacity. Additionally, the authors discovered that anti-
CD20 therapy significantly induces CD4+CD25+Foxp3+ regulatory T cells [21]. It has been
shown that NOD mice deficient for B cells from the birth fail to develop autoimmune diabe‐
tes [22]. Xiu, et al [23] directly tested how depletion of B cells influenced T1D pathogenesis
in wild-type NOD mice with an intact immune system. NOD female mice at early and late
pre-clinical stages of disease were treated with mouse anti-mouse CD20 mAbs. Short-term
anti-CD20 mAb treatment in 5-week old NOD female mice reduced B cell numbers by 95%,
decreased subsequent insulitis, and prevented diabetes in >60% of littermates. The treatment
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in 15-week old NOD mice was unable to prevent T1D but significantly delayed the process.
In contrast to the study described previously, this study failed to show any changes in T
cells and regulatory T cells [22]. The results of anti-CD20 therapy in the above T1D animal
models are encouraging. Further clinical studies are needed to determine whether anti-
CD20 therapy has the same efficacy in human T1D.
2.1.3. Clinical studies on anti-CD20 therapy in T1D
A randomized, double blind clinical study testing the effect of Rituximab on new-onset T1D
was conducted by the T1D TrialNet Anti-CD20 study group. The results were published in
New England Journal of Medicine 2009 [10]. In this well-designed clinical study, 87 patients
aged 8 to 40 years who had newly diagnosed T1D were assigned to either receive infusions
of 375 mg/m2 Rituximab (57 cases) or placebo (30 cases) on days 1, 8, 15, 22. The primary
outcome assessed 1 year after the first infusion, was geometric mean area under the curve
(AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test.
The results showed that at 1 year post treatment, the mean AUC for the level of C peptide
was significantly higher in the Rituximab group than in the placebo group. The levels of gly‐
cated hemoglobin and requirement of insulin were significantly reduced in Rituximab
group as compared to placebo group. Peripheral blood B lymphocytes were quickly deplet‐
ed in the Rituximab group, and slowly recovered with time. By the end of 1 year observa‐
tion, the levels of B lymphocytes increased to 69% of baseline. It is noted that the rate of C-
peptide loss did not accelerate with recovery of B cells between 6 months and 1 year.
Patients in Rituximab group had more incidences of adverse events, displaying mostly
grade 1 or grade 2 after the first infusion. The reactions appeared to be minimal with subse‐
quent infusions. No increased frequency of infection or neutropenia with Rituximab was re‐
ported. In this study, the authors observed significant reduction of serum IgM but not IgG
suggesting Rituximab may selectively deplete sub-populations of B cells. Based on the re‐
sults of one-year follow-up, anti-CD20 therapy is a promising approach for T1D treatment.
Whether repeating the course of anti-CD20 therapy is needed and whether this treatment
leads to long-term protection need to be further investigated.
A follow-up study on the patients enrolled in the clinical study described above attempted
to address how Rituximab infusion influences the levels of autoantibodies against islet anti‐
gens. Autoantibodies to insulin (IAAs), GAD65 (GADAs), insulinoma-associated protein 2
(IA2As), and ZnT8 (ZnT8As) were measured with radioimmunoassays. The results showed
that Rituximab markedly suppressed IAAs compared with the placebo injection but had a
much smaller effect on GADAs, IA2As and ZnT8As. A total of 40% (19 of 48) of Rituximab-
treated patients who were IAA positive became IAA negative versus 0 patient out of 29 pla‐
cebo-treated patients. In the subgroup (n=6) treated within 50 days of diabetes, IAAs were
markedly suppressed by Rituximab treatment in all patients for 1 year and for four patients
as long as 3 years despite of continuing insulin therapy. Independent of Rituximab treat‐
ment, the mean level of IAAs at study entry was markedly lower for patients who main‐
tained C-peptide levels during the first year of follow up in both Rituximab-treated and
placebo groups [24]. The results described above suggest that anti-CD20 therapy differen‐
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tially suppresses anti-islet autoantibodies. Further studies are needed to investigate whether
autoreactive B cell clones against islet antigens are differentially depleted.
As mentioned earlier, mouse studies have demonstrated that anti-CD20 therapy alters T
cells. It is of interest to know how Rituximab infusion affects T cell responses in human T1D.
This was explored in a follow-up study on patients in the above-described clinical trial Sur‐
prisingly, it is noted that Rituximab treatment leads to enhanced proliferative responses of T
cells to diabetes-associated islet-specific autoantigens, which are positively correlated with
C-peptide levels [25]. It is still unclear why B cell depletion enhances T cell proliferation. It is
likely to be related to the refill of immune system post B cell depletion by T cells through
homeostatic proliferation. Further studies are needed to characterize those T cells phenotyp‐
ically and functionally to determine whether those autoreactive T cells are beneficial or
harmful for controlling autoimmunity.
Drug resistance is the major reason of failure in the treatment of B cell lymphoma by Rituxi‐
mab [26, 27]. It had been unknown whether anti-CD20 therapy in autoimmune diseases,
such as T1D can also lead to drug resistance until a recent report indicating a potential
mechanism for the ineffectiveness of anti-CD20 therapy in T1D [28]. This animal study
showed that anti-CD20 efficiently depleted follicular but not marginal zone B cells. Interest‐
ingly, the islet infiltrated B cells lost their CD20 expression, which might explain the ineffec‐
tiveness of anti-CD20 therapy in late stage of T1D in NOD mice. Gradual recovery of the
antibodies against islet antigens further suggests that autoimmune B cells are unable to be
completely wiped out by anti-CD20 therapy. New drugs targeting the islet-infiltrated
CD20neg B cells, such as anti-CD19 antibodies may be needed to further improve the efficacy
of immunotherapy targeting B cells.
One of the most concerned issues regarding anti-CD20 therapy is the potential infection aris‐
en by B cell depletion [29]. Anti-CD20 therapy indeed leads to hypoimmunoglobulinemia
[30-32]. However, there is no significant increase in the incidence of infection during anti-
CD20 therapy, which is consistent with a recent report demonstrating that anti-CD20 thera‐
py does not deplete memory B cells specific to the antigens previously encountered [33, 34].
Another biggest concern of anti-CD20 therapy is anaphylaxis to anti-CD20 antibodies [35]
because the current clinically employed anti-CD20 antibodies like Rituximab are made from
animals. Humanized anti-CD20 antibodies are being developed, and are expected to over‐
come this severe adverse effect.
2.2. Anti-CD3 antibody therapy in type 1 diabetes
Given that T1D is a T cell-mediated autoimmune disease, T cell depletion therapy is expect‐
ed to be a promising approach in T1D therapy. Much attention to anti-CD3 therapy has been
drawn to the researchers and clinicians in the field of T1D. Over the years of basic and clini‐
cal studies, enormous progress has been made in terms of mechanism of action and the opti‐
mization of anti-CD3 therapy. Several clinical trials in new onset T1D are under way. In the
following section, we will discuss T1D anti-CD3 therapy including mechanism of action, an‐
imal studies, clinical studies, adverse effects as well as issues to be resolved, etc.
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2.2.1. Mechanism of action of anti-CD3 therapy
As what has been described in anti-CD20 therapy, anti-CD3 therapy works eventually
through non-selective depletion of T cells including CD4+ and CD8+ T cells. Currently, it is
believed that the mechanism of action of anti-CD3 therapy is largely beyond T cell deple‐
tion. In this section, we will discuss how anti-CD3 therapy works to preserve islet β cells.
2.2.1.1. Activation-induced cell death in anti-CD3 therapy
It is known that in the initial stage of anti-CD3 therapy, all T cells including CD4+ and CD8+
T cells are activated as evidenced by the expression of CD69. Activation-induced cell death
(AICD) is a major mechanism regulating central tolerance during T cell development in thy‐
mus. Yu et al reported that anti-CD3 triggered AICD in activated T cells in vitro [36], which
might explain anti-CD3 therapy-induced immune tolerance. However, the in vivo data are
controversial. While accumulating data showed that anti-CD3 therapy is able to induce T
cell apoptosis in vivo as it behaves in vitro, but others provided evidence showing that anti-
CD3 therapy does not induce T cell death but induce unresponsiveness to stimuli of mito‐
gens [37]. Therefore, anti-CD3 therapy is not just T cell depletion, but likely other
tolerogenic mechanisms participate in this process.
2.2.1.2. Anti-CD3 therapy promotes regulatory T cells
In 2003, an elegant study by Belghith, et al [38] reported that anti-CD3 treatment induced
TGF-β-producing T cells which was indispensable for the anti-CD3-induced immune toler‐
ance. A later study further confirmed this finding and demonstrated that anti-CD3 therapy
induced regulatory T cells through TGF-β released from phagocytes phagocytosing apoptot‐
ic T cells induced by anti-CD3 therapy in vivo [39]. Neutralizing TGF-β or blocking phagocy‐
tosis abrogated the induction of regulatory T cells [39]. Additionally, anti-CD3 therapy
might differentially deplete distinct subsets of T cells and preferentially preserve regulatory
T cells. Consistent with this concept, a recent report demonstrated anti-CD3 therapy in NOD
mice selectively depleted autoantigen-specific effector T cells but preserved regulatory T
cells [40]. The increase of regulatory T cells was not due to the conversion of regulatory T
cells from conventional T cells because all preserved regulatory T cells expressed helios
which is a natural regulatory T cell marker [40]. The resistance of natural regulatory T cells
to anti-CD3 depletion is not clear but may be associated with compromised activation of
apoptotic pathways in regulatory T cells in response to anti-CD3 therapy. Recently, Bisikir‐
ska et al [41] reported that anti-CD3 treatment in human T1D patients expanded CD8+ T
cells and induced Foxp3+ CD8+ regulatory T cells, suggesting that this type of regulatory T
cells might contribute to immune tolerance induced by anti-CD3 therapy.
2.2.1.3. Anti-CD3 therapy induces T cell anergy
Another form of immune tolerance is T cell anergy. To dissect the mechanism of action of
anti-CD3 therapy, it is interesting to know whether anti-CD3 therapy induces T cell anergy
in vivo. There are two forms of anti-CD3 antibodies based on their working principles, i.e.
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mitogenic and nonmitogenic antibodies. Nonmitogenic anti-CD3 antibody is thought to in‐
duce T cell tolerance mainly through the induction of T cell anergy. Smith reported that non‐
mitogenic anti-CD3 antibody treatment only delivers partial T cell activation signals thereby
inducing T cell unresponsiveness (anergy) [42]. This effect occurs not only in CD4+ T cells
but also in CD8+ T cells. Research data from Bluestone’s group show that in vivo treatment
of anti-CD3 antibodies induces long-term CD8+ T cell anergy [43-45]. The mechanism un‐
derlying anti-CD3 therapy induced T cell anergy is not known until a recent report from
Bluestone’s group showing that PD1-PDL1 interaction is required for maintaining long-term
T cell anergy and T1D protection [45]. Blocking PD1-PDL1 interaction quickly reverses T cell
anergy and the anergic T cells become pathogenic effector T cells. Under blockade of PD1-
PDL1 interaction, the protected NOD mice by anti-CD3 treatment quickly develop diabetes
[45]. The above data suggest that maintenance of anergic state of autoimmune T cells is es‐
sential, and PD1-PDL1 may play a pivotal role in this process.
2.2.2. Anti-CD3 therapy in T1D animal models
There are currently two T1D animal models that spontaneously develop diabetes under ge‐
netic susceptibility, NOD mice and diabetes-prone biobreeding (BB) rat. Although these two
T1D animal models have some similarities to human T1D, there are many differences be‐
tween animal and human in terms of disease progression. Nevertheless, studies on animal
models will definitely provide very useful information for the immunopathogenesis, pre‐
vention and treatment of T1D. Several clinical trials are based on promising results in ani‐
mal models including anti-CD3 therapy in new onset diabetes.
Anti-CD3 therapy for T1D was first tested in NOD mice. Chatenoud, et al [46] reported that
anti-CD3 treatment of adult NOD mice significantly inhibits the autoimmune process. Short-
term low-dose anti-CD3 treatment (5 μg/day i.v. for 5 consecutive days) prevented the oc‐
currence of an accelerated form of the disease induced by cyclophosphamide. When this
regimen was administered in adult NOD females with newly diagnosed diabetes, 64-80% of
treated mice obtained a complete remission of overt diabetes showing permanent normogly‐
cemia. It was noted that this remission was durable (>4 months) and was not associated the
disappearance of insulitis. Anti-CD3 treated mice failed to reject syngeneic islet graft but
maintained normal response to allogeneic skin grafts, whereas control untreated diabetic
NOD females rejected both, suggesting that anti-CD3 therapy reverses diabetes through in‐
ducing islet antigen-specific immune tolerance. This study also suggests that diabetes-re‐
versing effect can be obtained by transient targeting of the CD3/T-cell receptor without
massive T-cell debulking. As described earlier, this effect may be associated with diabetes-
protecting regulatory T cells induced by anti-CD3 therapy.
To improve the effectiveness of anti-CD3 therapy, a strategy of combination with islet anti‐
gens has been proposed to more effectively restore self-tolerance to islet antigens. Bresson,
et al [47] reported that anti-CD3 and nasal proinsulin combination therapy enhances remis‐
sion from recent-onset autoimmune diabetes in comparison to monotherapy with anti-CD3
or antigen alone. Further studies demonstrated the expansion of CD25+Foxp3+ and insulin
antigen-specific regulatory T cells producing IL-10, TGF-β and IL-4. When adoptively trans‐
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ferred, these cells could transfer immune tolerance to immunocompetent recent-onset dia‐
betic recipients and suppressed autoaggressive CD8+ responsive T cells. This strategy
would act more site-specifically thereby reducing the risk for systemic side effects. The same
group employed a mathematical disease model, and revealed that preexisting autoantibod‐
ies predict efficacy of oral insulin in combination with anti-CD3 antibodies to cure autoim‐
mune diabetes [48]. This study shows that NOD mice with higher pretreatment levels of
serum insulin-associated antigens (IAAs) responded with a much higher likelihood to com‐
bination therapy but not anti-CD3 monotherapy, indicating that IAAs may be a good bio‐
marker to predict a better capability of the mice in inducing insulin-specific regulatory T
cells after oral insulin immunization. Ablamunits, et al [49] reported recently that co-admin‐
istration of anti-CD3 and IL-1 receptor antagonist had synergistic effect on T1D reversal,
which showed that the combinatorial therapy led to persistent remission from islet inflam‐
mation. Whether the resolution of islet inflammation leads to regeneration of islet β cells
was not addressed in this report.
The outcomes from animal studies have provided very useful information for developing
anti-CD3-based therapeutic strategies for human T1D. Although the results of anti-CD3
therapy in human T1D are mixed, the preservation of β cell function in the current clinical
trial suggests that anti-CD3 therapy is a viable regimen for human T1D.
2.2.3. Anti-CD3 therapy in T1D clinical studies
The results of the first clinical trial using anti-CD3 therapy for human T1D were reported in
New England Journal of Medicine in 2002. Herold, et al [50] studied the effects of a nonacti‐
vating humanized mnonclonal antibody against CD3 (hOKT3gamma1 (Ala-Ala) on the loss
of insulin production in patients with recently diagnosed T1D. Within 6 weeks after diagno‐
sis, 24 patients were randomly assigned to receive either a single 14-day course of anti-CD3
treatment, or no antibody and, were followed for one year. The results showed that anti-
CD3 treatment maintained or improved insulin production after one year in 9 of the 12 pa‐
tients in the treatment group whereas only 2 of the 12 controls had a sustained response.
The treatment effect on insulin response lasted for at least 12 months after diagnosis. Glycat‐
ed hemoglobin level and insulin dose requiement were reduced in the anti-CD3 treatment
group. No severe adverse effect was observed, and the most common side effects were fe‐
ver, rash, and anemia. Clinical responses were associated with a change of CD4+ T cells to
CD8+ T cells ratios at 30 and 90 days after treatment with the responders showing reduced
CD4/CD8 ratios. This study provides initial encouraging results. Longer period of follow-up
would be needed to establish the long-term effectiveness of this therapy.
A clinical study was conducted using the similar protocol in the above-mentioned study but
with different doses at different injection times during the treatment course. The results
demonstrated significant improvement in C-peptide response to a mixed meal. The im‐
proved C-peptide responses were accompanied by reduced HbA1c and insulin require‐
ments. These results indicate that treatment with anti-CD3 antibody, hOKT3γ1 (Ala-Ala),
Teplizumab results in improved C-peptide responses and clinical parameters in T1D for at
least 2 years in the absence of continued immunosuppressive medications. In this study, be‐
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cause of severe adverse effect of the increased dose of Teplizumab, the patient enrollment
was stopped after 10 patients enrolled [51]. Among these patients, four drug-treated patients
were followed up for 5 years. Results showed that C-peptide responses were maintained.
During this study, it was found that increased dose of anti-CD3 antibodies caused severe
adverse effects without gaining improved therapeutic effect [52]. Thus, the dosing may need
to be further modified to gain the best benefit for the patients.
Recently, the results of a randomized and double blind clinical trial (clinicaltrial.gov, num‐
ber NCT00385697) conducted by multi-centers from different countries on anti-CD3 therapy
in treating new onset T1D was reported in Lancet journal [53]. In this 2-year trial, patients
aged 8-35 years who had been diagnosed with T1D for 12 weeks or fewer were enrolled and
treated at 83 clinical centers in North America, Europe, Israel and India. Participants re‐
ceived one of the three regimens of teplizumab infusions (14-day full dose, 14-day low dose,
or 6-day full dose, or placebo). Patients and study staff remain masked through to study clo‐
sure. 763 patients were screened, of whom 516 were randomized to receive 14-day full-dose
teplizumab (n=209), 14-day low dose teplizumab (n=102), 6-day full-dose teplizumab
(n=106), or placebo (n-99). Two patients in the 14-day full-dose group and one patient in the
placebo group did not start treatment, so 513 patients were eligible for efficacy analysis. The
primary outcome did not differ between groups at 1 year. Nonetheless, 5% (19/415) of pa‐
tients in the teplizumab groups were not taking insulin at 1 year, compared with no patients
in the placebo group at 1 year (p=0.03). All groups had similar incidences of adverse effects.
The most common clinical adverse event in the teplizumab groups was rash (220/417 [53%]
versus 20/99 [20%] in the placebo group). This study suggests that future studies of immu‐
notherapeutic intervention with Teplizumab might have increased success in prevention of
a decline in β-cell function and provision of glycemic control at reduced doses of insulin if
they target patients early after diagnosis of diabetes and children.
From the results of the above clinical trials, anti-CD3 therapy is a promising regimen for hu‐
man new onset T1D. However, its efficacy needs to be further improved. For this purpose,
combinatorial therapy is a rational approach [54, 55]. As described above, recent animal
studies demonstrated that anti-CD3 therapy combined with islet β cell antigens induced is‐
let antigen-specific immune tolerance and significantly improved the effectiveness of anti-
CD3 therapy in NOD mice. Anti-CD3 antibody combined with IL-1 receptor antagonist was
tested in NOD mice and showed significant improvement of therapeutic efficacy. Interna‐
tional multi-center clinical trials have tested the agents, anti-CD3, GAD, diapep227, insulin
immunization and IL-1 receptor antagonist, anakinra, separately. There is, thus far, no clini‐
cal trial testing the efficacy of combinatorial therapy of the above-mentioned agents in treat‐
ing T1D. Therefore, a phase 1 clinical trial may be needed in this respect.
2.3. Anti-thymoglobulin (ATG) therapy in type 1 diabetes
Simson, et al reported that ATG treatment (500 μg/mouse) at day 1 and day 3 attenuated
T1D development. It was noted that this T1D protection only presented when NOD mice
were at disease onset or in the late pre-diabetic phase (12 weeks of age). It was demonstrat‐
ed that when provided at 12 weeks of age, ATG reversed pancreatic insulitis, improved met‐
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abolic responses to glucose challenge, and rapidly increased frequency of antigen-
presenting cells in spleen and pancreatic lymph nodes. It was also found that ATG therapy
dramatically increased the frequency and functional activity of CD4+CD25+ regulatory T
cells. Adoptive transfer/cotransfer studies of T1D support that ATG therapy induces a stable
and transferable immunomodulatory repertoire in vivo. This study indicates that an induc‐
tion of immunoregulation, rather than simple lymphocyte depletion, contributes to the ther‐
apeutic efficacy of ATG therapy [56]. The same group reported that ATG therapy combined
with granulocyte-colony-stimulating factor (G-CSF) was remarkably effective at reversing
newly diagnosed diabetes in NOD mice and more efficacious than either agent alone. This
combination also afforded durable reversal from disease (>180 days post-onset) in animals
having pronounced hyperglycemia (i.e., up to 500 mg/dL). Mechanistically, this combination
therapy resulted in both immunological and physiological benefits, showing increased
CD4/CD8 ratios and splenic regulatory T cells, as well as increased pancreatic β cell area and
attenuated pancreatic inflammation [57].
Our unpublished data show that ATG therapy preferentially depletes naïve T cells, and
memory T cells are relatively preserved. In addition, ATG therapy largely spares
CD4+CD25+ regulatory T cells. Of interest, ATG therapy does not deplete antigen-specific T
cells but alters T cell responses to the previously experienced antigens, showing increased
levels of Th2 and IL-10-producing Tr1 cells, which might contribute to ATG therapy-in‐
duced T1D protection. In addition, post-ATG therapy CD4+CD25+ regulatory T cells display
memory-like T cells phenotypically, suggesting that those regulatory T cells might play an
important role in ATG therapy-induced long-lasting T1D protective effect.
Based on the animal studies described above, a couple of clinical trials using ATG, or ATG
combined with G-CSF in human T1D are ongoing (www.clinicaltrials.gov/NCT0116157,
www.clinicaltrials.gov/NCT00515099). The assessment of the effectiveness of ATG therapy
in human T1D await the outcomes from these clinical trials.
3. Cellular therapy of type 1 diabetes
T1D is characterized by the autoimmune destruction of insulin-producing β cells with loss
of insulin secretion. Patients with T1D have absolute requirement of insulin for survival.
While insulin is effective in lowering blood glucose, hypoglycemia, even life-threatening hy‐
poglycemia, is almost unavoidable with insulin treatment, as exogenous insulin cannot ex‐
actly mimic the profile of physiological insulin secretion. Other limitations of insulin
therapy include inconvenience of daily life, physical pain and high economic costs caused
by recurrent insulin injections.
Therefore, other strategies have been explored to preserve or restore β cell function in the
hope that endogenous insulin secretion will achieve better glycaemic control while reducing
episodes of severe hypoglycemia. As discussed above, immunotherapy, in particular the use
of immunomodulatory drugs has pulled much efforts. Both experimental and clinical data
demonstrate that some agents like anti-CD20 and anti-CD3 antibodies are effective in delay‐
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ing the process of β cell autoimmune destruction. However, no drugs have demonstrated to
prevent or reverse human T1D successfully in long-term.
More recently, many efforts have been focused on the use of stem cells as a potential thera‐
peutic strategy for T1D. So far, accumulating data from both experimental and clinical trials
have suggested that stem cell-based cellular therapy could be a promising approach for T1D
treatment.
3.1. Hematopoietic Stem Cell Transplantation(HST ) for T1D
The use of bone marrow transplantation (BMT) as a potential treatment for T1D was first
proposed in animal study in 1985 [58], showing that allogenic bone marrow transplantation
could prevent insulitis and overt diabetes in NOD mice. This concept was further substanti‐
ated by later animal study [59].
The first clinical trial to use hematopoietic stem cell transplantation in T1D patients was re‐
ported in 2003 [60]. The objective of the study was to stop autoimmune destruction of β cells
with immunosuppressive drugs and to “re-set”the impaired immunologic system with a re‐
constituted one using autologous HSCs in the expectations of preserving residual β cell
mass and facilitating endogenous mechanisms of β cell regeneration. With the above consid‐
erations, 15 newly diagnosed T1D patients were enrolled. All received high-dose immuno‐
suppression followed by autologous hematopoietic stem cell transplantation (AHST) within
6 weeks of diagnosis. During a 7- to 36-month follow-up (mean 18.8 months), 14 patients be‐
came insulin-free. β cell function was improved as evidenced by the increase in C-peptide
levels. No significant adverse effects were observed. The mechanism concerning the benefi‐
cial effects of HST is proposed to be associated with the generation of a more tolerant im‐
mune system, which blocks the autoimmune destruction of residual β cells. This hypothesis
appears to be consistent with a recent clinical observation showing that intra-pancreatic au‐
tologous bone marrow infusion has no beneficial effects on long-standing T1D patients with
absence of β cell function [61].
To date, it is unclear whether the beneficial effects of HST can be sustained because of the
lack of long-term follow-up study. Second, it is not known whether the beneficial effects of
HST are due to immune reconstitution via stem cell differentiation or modulating the func‐
tion of existing immune cells. Therefore, randomized controlled trials with prolonged fol‐
low-up are needed to confirm the results of current studies and to evaluate the full potential
of this regimen as a therapeutic option for T1D.
3.2. Umbilical cord blood (UCB) cell therapy for TID
Bone marrow is a rich source of stem cells, but its application is hampered by the limited availa‐
bility of bone marrow donors and the invasive procedure for cell collection. Human umbilical
cord blood (HUCB) is another source of stem cells. Compared to bone marrow, HUCB has
some major advantages such as easy availability, absence of risk to the donor, low risk of graft-
vs-host disease and tumorigenicity, high capacity for expansion [62]. UCB has been used suc‐
cessfully in transplantation for diseases like acute anemia, and sickle cell anemia [63]. There
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have been both animal and clinical studies evaluating the use of UCB cells as a potential thera‐
py for T1D. The rationale is based on experimental studies. In vitro cultures of HUCB can yield
islet-like structures capable of insulin and C-peptide production [64]. In vivo, human cord
blood-derived cells is also shown to be able to differentiate into islet cells when transfused into
2 day old NOD-scid mice [65]. A recent report demonstrated that cord blood-derived multipo‐
tent stem cells reversed T1D through islet β cell regeneration following immune modulation
[66]. Second, UCB contains a population of immature unprimed functional regulatory T cells.
Theoretically, these cells could limit inflammatory reaction and anergize effector T cells, which
are believed to mediate cellular autoimmune processes. In addition, UCB stem cells may act as
nurse cells to stimulate the proliferation of new islets from the remaining viable tissue [67].
Ende et al. [68, 69] reported in two separate studies that infusions of HUCB improved hyper‐
glycemia and diabetic nephropathy in obesity-induced diabetic mice. In addition, nonobese di‐
abetic (NOD) mice can be protected from developing insulitis and diabetes by HUCB dose-
dependently. However, the results of available clinical study is disappointing. In a recently
completed phase I clinical study [70], 24 children aged 3.4-6.9 years, with new onset T1D re‐
ceived a single autologous UBC infusion within 6 months of diagnosis. After 2 years of follow-
up, there was no evidence of reservation of β cell function, as evaluated by the area under the
curve C-peptide that was 2% of baseline 2 years after UBC infusion, despite that the numbers of
regulatory T cells (Tregs) and naïve Tregs were increased 6 and 9 months after. In that study,
there are several possibilities as to why UCB infusion may fail to preserve β cell function. First,
the stem cell number is insufficient. Second, there exist memory T cells refractory to regulation
by Tregs. Finally, it cannot be excluded that the UCB cells from the T1D patients may have in‐
trinsic defects with compromised biological function. In future, autologous or allogeneic trans‐
plantation with expanded UBC Tregs either alone or in combination of immunomodulatory
drugs may be worth trying. Importantly, randomized controlled studies are needed before de‐
finitive conclusions can be finally reached.
3.3. Mesenchymal stem cell therapy for TID
Mesenchymal stem cells (MSCs) were originally identified by Friedenstein et al. in 1976 [71]
in the bone marrow as a fibroblast-like cell population capable of generating osteogenic pre‐
cursors. MSCs from the bone marrow (BM) are a heterogeneous, stromal population of mul‐
tipotent non-hematopoietic progenitor cells capable of differentiating into multiple
mesenchymal lineages including bone, fat and cartilage. In addition to bone marrow, MSCs
have been found to be present in other tissues such as adipose tissue, umbilical cord blood,
synovial membrane, skeletal muscle, dermis, deciduous teeth, pericytes, trabecular bone, ar‐
ticular cartilage, umbilical cord, placenta, liver and spleen. It is now known that MSCs are
able to differentiate into mesodermal and non-mesodermal cell lineages, including osteo‐
cytes, adipocytes, chondrocytes, myocytes, cardiomyocytes, fibroblasts, myofibroblasts, epi‐
thelial cells, and neurons [72].
In addition to their pluripotency to differentiate, MSCs have high immunomodulatory ca‐
pacity. The immunomodulatory property of MSCs are associated with their inhibitory ef‐
fects on the proliferation and differentiation of both T cells and B cells, as well as dendritic
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cell (DC) [73]. Moreover, MSCs can modulate immune response through stimulating the
production of CD8+ Treg (regulatory T cells) [74]. MSCs are known to secrete a variety of
trophic mediators such as growth factors and cytokines (M-CSF, IL-6, IL-11, IL-15, SCF,
VEGF) that are involved in the regulation of immune response and hematopoieses. This
could be a major mechanism underlying the immunomodulatory action of MSCs. Recently,
MSCs have been used in clinical trials for the treatment of acute graft-versus-host disease
(GVHD) following allogeneic HSC transplantation [75,76], and for autoimmune diseases
such as multiple sclerosis and Crohn disease [77,78]. Another striking characteristic of MSCs
is the ability to differentiate into insulin-producing cells (IPCs). In vitro, MSCs can be differ‐
entiated into IPCs when cultured under proper conditions. The types of MSCs that have
been successfully induced to generate IPCs includes BM-MSCs, umbilical cord blood MSCs
(UCB-hMSCs), pancreatic MSCs and adipose-derived MSCs,etc. [79].
By now, the use of MSCs for treatment of diabetes have been explored in two animal studies. In
a model of murine STZ-induced diabetes, co-administration of BM cells with syngeneic or
semi-allogeneic MSCs normalized blood glucose and serum insulin levels. The beneficial effect
of this treatment does not seem due to the reconstitution of the damaged islet cells from the
transplant since no donor-derived β cells were found in the recovered animals. Instead, the
benefits may be due to the immunosuppressive effect of MSCs on the β cell-specific T cell re‐
sponse since MSCs injection caused the disappearance of beta-cell-specific T lymphocytes from
diabetic pancreas, which may allow the regeneration of recipient-derived pancreatic insulin-
secreting cells [80]. In another study [81], the mechanism underlying the beneficial effects of
MSCs on blood glucose was investigated in a diabetic rat model induced by high-fat diet/strep‐
tozotocin (STZ) administration. Autologous MSCs were administered either 1 or 3 weeks after
STZ injection. Infusion of MSCs during the early phase not only promoted β cell function but
also ameliorated insulin resistance, whereas infusion in the late phase merely ameliorated in‐
sulin resistance. The improved insulin sensitivity induced by MSCs infusion is associated with
an increase of GLUT4 expression and an elevation of phosphorylated insulin receptor sub‐
strate 1 (IRS-1) and Akt (protein kinase B) in insulin target tissues.
Taken together, these in vitro and in vivo experiments suggest that multiple mechanisms
may be involved for the beneficial effect of MSCs on blood glucose control in T1D. Thus far,
the use of MSCs to treat T1D is limited to animal studies. The efficacy of MSCs to treat pa‐
tients with T1D needs to be further evaluated in well-designed clinical trials.
In conclusion, both anti-lymphocyte antibody-based and cellular therapies are promising in
stopping ongoing autoimmunity against islet antigens and likely leading to a hopeful resto‐
ration of self-tolerance. The regimens combining anti-lymphocyte antibodies, islet antigens
and cellular therapies could maximize the preventive and/or therapeutic efficacy for T1D.
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